Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study
View ORCID ProfileGJ Connett, S Maguire, TC Larcombe, N Scanlan, SS Shinde, T Muthukumarana, A Bevan, View ORCID ProfileRH Keogh, View ORCID ProfileJP Legg
doi: https://doi.org/10.1101/2024.03.15.24304343
GJ Connett
1National Institute for Health Research, Southampton respiratory Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
S Maguire
3Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
TC Larcombe
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
N Scanlan
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
SS Shinde
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
T Muthukumarana
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
A Bevan
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
RH Keogh
3Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
JP Legg
1National Institute for Health Research, Southampton respiratory Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK

Data Availability
All data produced in the present work are contained in the manuscript
Posted March 16, 2024.
Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study
GJ Connett, S Maguire, TC Larcombe, N Scanlan, SS Shinde, T Muthukumarana, A Bevan, RH Keogh, JP Legg
medRxiv 2024.03.15.24304343; doi: https://doi.org/10.1101/2024.03.15.24304343
Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study
GJ Connett, S Maguire, TC Larcombe, N Scanlan, SS Shinde, T Muthukumarana, A Bevan, RH Keogh, JP Legg
medRxiv 2024.03.15.24304343; doi: https://doi.org/10.1101/2024.03.15.24304343
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)